[Federal Register: May 12, 2005 (Volume 70, Number 91)]
[Notices]
[Page 25063-25067]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr12my05-94]
[[Page 25063]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Feasibility and Impact of Influenza Vaccination by Pediatricians
of Household Contacts of Children Less Than Two Years
Announcement Type: New.
Funding Opportunity Number: RFA IP05-097.
Catalog of Federal Domestic Assistance Number: 93.185.
Key Dates:
Letter of Intent Deadline: June 13, 2005.
Application Deadline: June 27, 2005.
I. Funding Opportunity Description
Authority: Section 317(k)(1) of the Public Health Service Act, 42
U.S.C. 247b(k)(1), as amended.
Background: Influenza is associated with the hospitalization of
approximately two out of every 1,000 children aged less than two years
old each year on average. Influenza hospitalization rates up to five
times higher have been reported among children aged zero to five months
as compared with those 6-23 months. Beginning with the 2004-2005
influenza season, influenza vaccination was fully recommended for
children aged 6-23 months and for household contacts and out-of-home
caregivers of children aged less than two years. Since children aged
less than six months cannot be vaccinated against influenza and because
of incomplete protection from influenza among vaccinated children aged
6-23 months, vaccination of contacts is an important means to protect
children less than two years old from influenza. Currently, no systems
have been developed to reach household contacts of these young
children. Evaluation of mechanisms to vaccinate household contacts of
children aged less than two years, and particularly contacts of
children aged less than six months, and an assessment of the impact on
influenza in children with household contact vaccination are needed.
Information about the relative benefit of household contact vaccination
of children less than two years is particularly important when facing
influenza vaccine shortage as occurred in 2004-2005 and is expected to
occur at least in the early stages of a pandemic.
Although a multi-pronged approach will likely be necessary to
maximize vaccination of household contacts and out-of-home caregivers
of young children, one source for household contact vaccination may be
pediatricians who see young children on a regular basis for newborn
check-ups and routine immunizations. Pediatricians could offer
influenza vaccine to household contacts as well, at the same or
subsequent visits. Vaccination of adults and older children in the
household at the same visit as the child aged less than two years would
offer convenience and limit missed opportunities to vaccinate these
contacts.
We propose a study to assess the feasibility and impact of
influenza vaccination for household contacts of children less than two
years of age.
Purpose: The purpose of the program is to:
1. Evaluate the feasibility of offering influenza vaccination to
household contacts of children less than two years of age by
pediatricians.
2. Evaluate the impact of influenza vaccine coverage among
household contacts on influenza illness in children less than six
months and 6-23 months of age.
This program addresses the ``Healthy People 2010'' focus area(s) of
Immunization and Infectious Diseases.
Measurable outcomes of the program will be in alignment with one
(or more) of the following performance goal(s) for the National
Immunization Program (NIP): Reduce the number of indigenous cases of
vaccine-preventable diseases (VPD).
Research Objectives: 1. To evaluate the feasibility of offering
influenza vaccination to adult and pediatric household contacts of
children less than two years of age by pediatricians.
2. To evaluate the impact of influenza vaccine coverage among
household contacts on influenza illness in children less than six
months and 6-23 months of age in comparison to vaccination of the child
alone after controlling for important co-factors (e.g., day care
attendance, maternal influenza vaccination, household smoke exposure).
Activities: Awardee activities for this program are as follows:
1. Conduct a prospective case-control study among children and
families enrolled in a group of pediatric practices in one or more
geographic locations. Practices would be randomized to offering
influenza vaccination to adult and pediatric household contacts of
children less than two years of age at the pediatrician's office during
or after the child's medical visit and educating the child's parent
about the recommendation for vaccination of all of the child's
household contacts versus education alone. For the intervention
practices, evening vaccination clinics and walk-in influenza
vaccination-only services for household contacts would also be
provided. Influenza vaccine would be offered initially beginning on
September 1, or as soon as vaccine is available for those children who
would need two doses the first year and would begin October 1 for
children who need only one dose. Vaccination efforts would continue
through December 31. Educational materials including the Vaccine
Information Statement should be provided to pediatric offices and staff
and parents/guardians regarding the new recommendation and the
rationale for the study.
2. During the time that influenza is circulating in the community
(based on local virologic surveillance), a sample of children aged less
than two years who come for medical care to intervention and non-
intervention pediatric offices with fever and one or more acute
respiratory symptoms or febrile seizure (ARI) will have the influenza
vaccination histories of the child, parents and other household members
collected plus other demographic information, such as daycare
attendance and household smoke exposure. In addition, a respiratory
specimen will be collected for rapid influenza testing. Influenza
testing is essential since children in this age group experience an
average of six respiratory illnesses a year and even during peak
influenza activity, only 20-35 percent of respiratory illnesses would
be expected to be influenza related.
3. During the same period, parents of children who come for medical
care to the clinic without respiratory illness (controls) will be asked
to complete a questionnaire on vaccination status of the child and
household contacts and other demographic information. Controls should
be recruited 2:1 with ill case children during the same week as ill
children and matched by age within plus or minus one month of age for
children less than six months, plus or minus two months for children
aged 6-12 months, and plus or minus four months for children aged 13-23
months.
4. An audit of a sample of charts of children 6-23 months should be
reviewed to assess the overall vaccination rate among children 6-23
months in the practice and to validate vaccination for a sample of
children enrolled in the study.
5. A survey of a sample of families should be conducted at the end
of the year to assess vaccination rates of household contacts of
children less than six months and 6-23 months.
[[Page 25064]]
6. Physicians and nursing and administrative staff in the
participating practices should be interviewed using a standard data
collection instrument to assess logistical issues and difficulties
anticipated or encountered both before and during implementation of the
protocol to vaccinate the household contacts.
7. Because the severity and timing of influenza activity and the
influenza vaccine antigenic match can vary substantially from year to
year, the study should be conducted and data collected from two
complete influenza seasons.
8. Analysis should include assessment of:
a. Vaccination rates of children and their household contacts
compared between non-ARI controls, patients with ARI who test positive
for influenza and patients with ARI who test negative for influenza.
b. Rates of laboratory-confirmed, medically-attended influenza
illness among patients aged less than two years should be calculated
among the participating practices after weighting based on the number
of days and percentage of patients with ARI that are sampled.
c. The following influenza vaccine effectiveness estimates should
be calculated: (1) Effectiveness in preventing influenza among children
6 to 23 months through vaccination of children in this age group, and
(2) effectiveness in preventing influenza among household contacts of
children less then six months and 6 to 23 months through vaccination of
children in these two age groups.
d. Vaccination rates of ARI and non-ARI controls household contacts
between those practices with and without adult vaccination services
should be compared to assess the success of the contact vaccination
program.
e. Sample sizes needed for analysis must be included.
In a cooperative agreement, CDC staff is substantially involved in
the program activities, above and beyond routine grant monitoring.
CDC Activities for this program are as follows:
1. Provide CDC investigators to monitor the cooperative agreement
as protocol investigators and project officer(s).
2. Provide consultation, scientific, and technical assistance in
designing and conducting the project. Assist in the development of
Institutional Review Boards (IRB) approval review by all cooperating
institutions and CDC.
3. Participate in data analysis and interpretation, and co-
authoring of manuscripts.
4. Participate in publication and dissemination of findings.
II. Award Information
Type of Award: Cooperative Agreement.
CDC involvement in this program is listed in the Activities Section
above.
Mechanism of Support: R01.
Fiscal Year Funds: 2005 for Year One.
Approximate Total Funding: $302,250 for Year One (This amount is an
estimate, includes direct and indirect costs, and is subject to
availability of funds.)
Approximate Number of Awards: One.
Approximate Average Award: $302,250 Year One and $300,750 Year Two
(These amounts include direct and indirect costs).
Floor of Award Range: None.
Ceiling of Award Range: $302,250 (This ceiling is for the first 12-
month budget period and include direct and indirect costs.)
Anticipated Award Date: August 31, 2005.
Budget Period Length: 12 Months.
Project Period Length: 2 Years.
Throughout the project period, CDC's commitment to continuation of
awards will be conditioned on the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required
reports), and the determination that continued funding is in the best
interest of the Federal Government.
III. Eligibility Information
III.1. Eligible Applicants
Applications may be submitted by public and private nonprofit
organizations and by governments and their agencies, such as:
Public nonprofit organizations
Private nonprofit organizations
Universities
Colleges
Research institutions
Hospitals
Community-based organizations
Faith-based organizations
Federally recognized Indian tribal governments
Indian tribes
Indian tribal organizations
State and local governments or their Bona Fide Agents
(this includes the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, the Commonwealth of the Northern Marianna
Islands, American Samoa, Guam, the Federated States of Micronesia, the
Republic of the Marshall Islands, and the Republic of Palau)
Political subdivisions of States (in consultation with
States)
A Bona Fide Agent is an agency/organization identified by the state
as eligible to submit an application under the state eligibility in
lieu of a state application. If you are applying as a bona fide agent
of a state or local government, you must provide a letter from the
state or local government as documentation of your status. Place this
documentation behind the first page of your application form.
III.2. Cost Sharing or Matching
Matching funds are not required for this program.
III.3. Other
CDC will accept and review applications with budgets greater than
the ceiling of the award range.
Special Requirements: If your application is incomplete or non-
responsive to the requirements listed in this section, it will not be
entered into the review process. You will be notified that your
application did not meet submission requirements.
Late applications will be considered non-responsive. See
section ``IV.3. Submission Dates and Times'' for more information on
deadlines
. Note: Title 2 of the United States Code Section 1611
states that an organization described in Section 501(c)(4) of the
Internal Revenue Code that engages in lobbying activities is not
eligible to receive Federal funds constituting an award, grant, or
loan.
Individuals Eligible To Become Principal Investigators: Any
individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented
racial and ethnic groups as well as individuals with disabilities are
encouraged to apply.
Additional Principal Investigator qualifications are as follows:
Previous demonstration of ability to conduct and publish
peer-reviewed epidemiologic studies on vaccine preventable diseases.
Submission of letters of support.
Be able to initiate the study the first year of funding
and have complete data for two influenza seasons.
[[Page 25065]]
IV. Application and Submission Information
IV.1. Address To Request Application Package
To apply for this funding opportunity, use application form PHS 398
(OMB number 0925-0001 rev. 9/2004). Forms and instructions are
available in an interactive format on the CDC Web site, at the
following Internet address: http:// www.cdc.gov/ od/pgo/ forminfo.htm.
Forms and instructions are also available in an interactive format
on the National Institutes of Health (NIH) web site at the following
Internet address: http://grants.nih.gov/grants/funding/phs398/phs398.html
.
If you do not have access to the Internet, or if you have
difficulty accessing the forms on-line, you may contact the CDC
Procurement and Grants Office Technical Information Management Section
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to
you.
IV.2. Content and Form of Application Submission
Letter of Intent (LOI): Your LOI must be written in the following
format:
Maximum number of pages: 2
Font size: 12-point unreduced
Single spaced
Paper size: 8.5 by 11 inches
Page margin size: One inch
Printed only on one side of page
Written in plain language, avoid jargon
Your LOI must contain the following information:
Descriptive title of the proposed research
Name, address, E-mail address, telephone number, and FAX
number of the Principal Investigator
Names of other key personnel
Participating institutions
Number and title of this Announcement
Application: Follow the PHS 398 application instructions for
content and formatting of your application. For further assistance with
the PHS 398 application form, contact PGO-TIM staff at 770-488-2700, or
contact GrantsInfo, Telephone (301) 435-0714, E-mail:
GrantsInfo@nih.gov.
Your research plan should address activities to be conducted over
the entire project period.
You are required to have a Dun and Bradstreet Data Universal
Numbering System (DUNS) number to apply for a grant or cooperative
agreement from the Federal government. Your DUNS number must be entered
on line 11 of the face page of the PHS 398 application form. The DUNS
number is a nine-digit identification number, which uniquely identifies
business entities. Obtaining a DUNS number is easy and there is no
charge. To obtain a DUNS number, access http://www.dunandbradstreet.com
or call 1-866-705-5711.
For more information, see the CDC Web site at: http://www.cdc.gov/od/pgo/funding/pubcommt.htm
.
This announcement uses the modular budgeting as well as non-modular
budgeting formats. See: http://grants.nih.gov/grants/funding/modular/modular.htm
for additional guidance on modular budgets. Specifically,
if you are submitting an application with direct costs in each year of
$250,000 or less, use the modular budget format. Otherwise, follow the
instructions for non-modular budget research grant applications.
Additional requirements that may require you to submit additional
documentation with your application are listed in section ``VI.2.
Administrative and National Policy Requirements.''
IV.3. Submission Dates and Times
LOI Deadline Date: June 13, 2005.
CDC requests that you send a LOI if you intend to apply for this
program. Although the LOI is not required, not binding, and does not
enter into the review of your subsequent application, the LOI will be
used to gauge the level of interest in this program, and to allow CDC
to plan the application review.
Application Deadline Date: June 27, 2005.
Explanation of Deadlines: LOIs must be received in the CDC Office
of Public Health Research (OPHR) and applications must be received in
the CDC Procurement and Grants Office by 4 p.m. Eastern Time on the
deadline date. If you submit your application by the United States
Postal Service or commercial delivery service, you must ensure that the
carrier will be able to guarantee delivery by the closing date and
time. If CDC receives your submission after closing due to: (1) carrier
error, when the carrier accepted the package with a guarantee for
delivery by the closing date and time, or (2) significant weather
delays or natural disasters, you will be given the opportunity to
submit documentation of the carriers guarantee. If the documentation
verifies a carrier problem, CDC will consider the submission as having
been received by the deadline.
This announcement is the definitive guide on LOI and application
content, submission address, and deadline. It supersedes information
provided in the application instructions. If your application does not
meet the deadline above, it will not be eligible for review, and will
be discarded. You will be notified that you did not meet the submission
requirements.
CDC will not notify you upon receipt of your submission. If you
have a question about the receipt of your LOI or application, first
contact your courier. If you still have a question concerning your LOI,
contact the OPHR staff at 404-371-5277. If you still have a question
concerning your application, contact the PGO-TIM staff at: 770-488-
2700. Before calling, please wait two to three days after the
submission deadline. This will allow time for submissions to be
processed and logged.
IV.4. Intergovernmental Review of Applications
Your application is subject to Intergovernmental Review of Federal
Programs, as governed by Executive Order (EO) 12372. This order sets up
a system for state and local governmental review of proposed federal
assistance applications. You should contact your state single point of
contact (SPOC) as early as possible to alert the SPOC to prospective
applications, and to receive instructions on your state's process.
Click on the following link to get the current SPOC list: http://www.whitehouse.gov/omb/grants/spoc.html
.
IV.5. Funding Restrictions
Restrictions, which must be taken into account while writing your
budget, are as follows:
Construction
Real estate lease or purchase
Vehicle purchase
Vehicle lease or rental
Funds relating to the conduct of research will not be
released until the appropriate assurances and Institutional Review
Board approvals are in place.
Reimbursement of pre-award costs is not allowed. Awarded
funds may not be used for any of the above restrictions with the
exception of vehicle rental directly associated with travel necessary
to accomplish the requirements of the project and for incidental
expenses associated with travel to meetings directly relating to the
project.
If you are requesting indirect costs in your budget, you must
include a copy of your indirect cost rate agreement. If your indirect
cost rate is a provisional rate, the agreement should be less than 12
months of age.
[[Page 25066]]
IV.6. Other Submission Requirements
LOI Submission Address: Submit your LOI by express mail or delivery
service to: Mary Lerchen, DrPH, Scientific Review Administrator, CDC/
Office of Public Health Research, One West Court Square, Suite 7000, MS
D-72, Telephone: 404-371-5277, Fax: 404-371-5215, E-mail:
MLerchen@cdc.gov.
Application Submission Address: Submit the original and one hard
copy of your application by mail or express delivery service to:
Technical Information Management--RFA IP05-097, CDC Procurement and
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341.
At the time of submission, four additional copies of the
application, and all appendices must be sent to: Mary Lerchen, DrPH,
Scientific Review Administrator, CDC/Office of Public Health Research,
One West Court Square, Suite 7000, MS D-72, Telephone: 404-371-5277,
Fax: 404-371-5215, E-mail: MLerchen@cdc.gov.
Applications may not be submitted electronically at this time.
V. Application Review Information
V.1. Criteria
Applicants are required to provide measures of effectiveness that
will demonstrate the accomplishment of the various identified
objectives of the cooperative agreement. Measures of effectiveness must
relate to the performance goals stated in the ``Purpose'' section of
this announcement. Measures must be objective and quantitative, and
must measure the intended outcome. These measures of effectiveness must
be submitted with the application and will be an element of evaluation.
The goals of CDC-supported research are to advance the
understanding of biological systems, improve the control and prevention
of disease and injury, and enhance health. In the written comments,
reviewers will be asked to evaluate the application in order to judge
the likelihood that the proposed research will have a substantial
impact on the pursuit of these goals.
The scientific review group will address and consider each of the
following criteria equally in assigning the application's overall
score, weighting them as appropriate for each application. The
application does not need to be strong in all categories to be judged
likely to have major scientific impact and thus deserve a high priority
score. For example, an investigator may propose to carry out important
work that by its nature is not innovative, but is essential to move a
field forward.
The review criteria are as follows:
Capability Demonstration: The application will be evaluated based
on response to all lettered and numbered items listed under Activities,
and demonstration of capability of conducting these activities.
Approach: Are the conceptual framework, design, methods, and
analyses adequately developed, well-integrated, and appropriate to the
aims of the project? Does the applicant acknowledge potential problem
areas and consider alternative methods to address these problems? The
application will also be evaluated based on: Appropriateness of power
and sample size estimates; methodology for assessing influenza vaccine
effectiveness by vaccinating household contacts in preventing illness
in children 0-5 months and 6-23 months.
Investigator: Is the investigator appropriately trained and well
suited to carry out this work? Is the work proposed appropriate to the
experience level of the principal investigator and other researchers
(if any)? The extent to which the applicant's plan describes the
organizational structure and procedures and identifies all
participating persons and groups including identifying key professional
staff and their roles and responsibilities. Past experience of key
professional staff in conducting clinical pediatric epidemiologic
research in vaccine preventable diseases, including past experience in
epidemiological assessment of vaccine effectiveness. Previous
demonstration of ability to conduct and publish peer-reviewed
epidemiologic studies on vaccine preventable diseases. Submission of
letters of support.
Environment: Does the scientific environment in which the work will
be done contribute to the probability of success? Do the proposed
activities take advantage of unique features of the scientific
environment or employ useful collaborative arrangements? Is there
evidence of institutional support? Are letters of support included, if
appropriate?
Past experience working in pediatric outpatient clinics and with
pediatric providers in conducting clinical research on vaccines.
Support from non-applicant supporting agencies, institutions,
organizations, laboratories, consultants, etc., indicated in
applications operational plan. Do not include letters of support from
CDC personnel.
Clear definition of the populations that would be studied,
including geographic description and population sizes and socio-
economic and racial-ethnic makeup.
Additional Review Criteria: In addition to the above criteria, the
following items will be considered in the determination of scientific
merit and priority score:
A clear understanding of the background and objectives of
this cooperative agreement program.
A clear understanding of the requirements,
responsibilities, constraints, and complexities that may be encountered
in establishing and conducting the study.
Protection of Human Subjects from Research Risks: Does the
application adequately address the requirements of Title 45 Part 46 for
the protection of human subjects? The involvement of human subjects and
protections from research risk relating to their participation in the
proposed research will be assessed.
Inclusion of Women and Minorities in Research: Does the application
adequately address the CDC Policy requirements regarding the inclusion
of women, ethnic, and racial groups in the proposed research? This
includes: (1) The proposed plan for the inclusion of both sexes and
racial and ethnic minority populations for appropriate representation;
(2) The proposed justification when representation is limited or
absent; (3) A statement as to whether the design of the study is
adequate to measure differences when warranted; and (4) A statement as
to whether the plans for recruitment and outreach for study
participants include the process of establishing partnerships with
community(ies) and recognition of mutual benefits.
Budget: The reasonableness of the proposed budget and the requested
period of support in relation to the proposed research. The priority
score should not be affected by the evaluation of the budget.
V.2. Review and Selection Process
Applications will be reviewed for completeness by the Center for
Scientific Review (CSR), and for responsiveness by OPHR. Incomplete
applications and applications that are non-responsive to the
eligibility criteria will not advance through the review process.
Applicants will be notified that their application did not meet
submission requirements.
Applications that are complete and responsive to the announcement
will be evaluated for scientific and technical merit by an appropriate
peer review group or charter study section, a Special Emphasis Panel
(SEP), convened by the OPHR in accordance with the review criteria
listed above. As part of the
[[Page 25067]]
initial merit review, all applications will:
Undergo a peer review by a Special Emphasis Panel. The SEP
will be selected from the NIH pool of scientists or recommendations
from the National Immunization Program to serve as reviewers on SEPs.
Applications will be ranked for the secondary review according to
scores submitted by the SEP. Only those applications deemed to have the
highest scientific merit by the review group, generally the top half of
the applications under review, will be discussed and assigned a
priority score.
Receive a written critique.
Receive a second programmatic level review by the Office
of Science, National Immunization Program.
Award Criteria: Criteria that will be used to make award decisions
during the programmatic review include:
Scientific merit (as determined by peer review)
Availability of funds
Programmatic priorities
Proposed budget
V.3. Anticipated Announcement and Award Dates
Anticipated Award Date: August 31, 2005.
VI. Award Administration Information
VI.1. Award Notices
Successful applicants will receive a Notice of Award (NoA) from the
CDC Procurement and Grants Office. The NoA shall be the only binding,
authorizing document between the recipient and CDC. The NoA will be
signed by an authorized Grants Management Officer, and mailed to the
recipient fiscal officer identified in the application.
Unsuccessful applicants will receive notification of the results of
the application review by mail.
VI.2. Administrative and National Policy Requirements
45 CFR Part 74 and Part 92.
For more information on the Code of Federal Regulations, see the
National Archives and Records Administration at the following Internet
address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements apply to this project:
AR-1 Human Subjects Requirements
AR-2 Requirements for Inclusion of Women and Racial and
Ethnic Minorities in Research
AR-6 Patient Care
AR-7 Executive Order 12372
AR-8 Public Health System Reporting Requirements
AR-10 Smoke-Free Workplace Requirements
AR-11 Healthy People 2010
AR-12 Lobbying Restrictions
AR-14 Accounting System Requirements
AR-15 Proof of Non-Profit Status
AR-22 Research Integrity
AR-23 States and Faith-Based Organizations
AR-24 Health Insurance Portability and Accountability Act
Requirements
Additional information on these requirements can be found on the
CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm
.
VI.3. Reporting
You must provide CDC with an original, plus two hard copies of the
following reports:
1. Interim progress report, (use form PHS 2590, OMB Number 0925-
0001, rev. 9/2004 as posted on the CDC Web site) quarterly during the
project. The progress report sent no later than 90 days before the end
of the first half of the budget period will serve as your non-competing
continuation application, and must contain the following additional
elements:
a. Reports of participant enrollment.
b. Progress in analysis.
c. Progress Toward Measures of Effectiveness.
d. Additional Information Requested by Program.
2. Financial status report, no more than 90 days after the end of
the budget period.
3. Final financial and performance reports, no more than 90 days
after the end of the project period.
These reports must be mailed to the Grants Management Specialist
listed in the ``Agency Contacts'' section of this announcement.
VII. Agency Contacts
We encourage inquiries concerning this announcement. For general
questions, contact: Technical Information Management Section, CDC
Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341,
Telephone: 770-488-2700.
For scientific/research issues, contact: Susan Chu, PhD, MSPH,
Extramural Program Official, Centers for Disease Control and
Prevention, MS E-05, 1600 Clifton Road, Atlanta, GA 30333, Telephone:
404 639-8727, E-mail: SChu@cdc.gov.
For questions about peer review, contact: Mary Lerchen, DrPH,
Scientific Review Administrator, CDC/Office of Public Health Research,
One West Court Square, Suite 7000, MS D-72, Telephone: 404-371-5277,
Fax: 404-371-5215, E-mail: MLerchen@cdc.gov.
For financial, grants management, or budget assistance, contact:
Mattie Jackson, Grants Management Specialist, CDC Procurement and
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341, Telephone: 770-
488-2696, E-mail: mij3@cdc.gov.
VIII. Other Information
This and other CDC funding opportunity announcements can be found
on the CDC Web site, Internet address: http://www.cdc.gov Click on ``Funding'' then ``Grants and Cooperative Agreements.'' http://www.cdc.gov/nip.
and http://www.cdc.gov/flu.
Dated: May 6, 2005.
William P. Nichols,
Director, Procurement and Grants Office, Centers for Disease Control
and Prevention.
[FR Doc. 05-9453 Filed 5-11-05; 8:45 am]
BILLING CODE 4163-18-P